Herpes simplex vaccine - Xenova

Drug Profile

Herpes simplex vaccine - Xenova

Alternative Names: DISC HSV; DISC HSV-1; DISC HSV-2; GW 419458; TA HSV

Latest Information Update: 17 Jan 2005

Price : $50

At a glance

  • Originator Xenova Group
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Herpes simplex virus infections

Most Recent Events

  • 17 Jan 2005 The DISC-HSV Vector platform has been licensed to Oxxon Therapeutics worldwide
  • 15 Oct 2001 The agreement with GSK to co-develop TA HSV will be terminated effective January 2002
  • 15 Oct 2001 Discontinued-II for Herpes simplex virus infections in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top